Lorazepam Use Linked to Shorter PFS, OS in Several Cancers
Lorazepam use may impact progression-free survival and overall survival in patients with a range of cancers, new research suggests.
Diagnosis & Disease Information
RFS Should Not Be Surrogate for OS in Trials of Adjuvant Immunotherapy, Researchers Say
Relapse-free survival should not be used as a surrogate for overall survival in cancer trials testing adjuvant immunotherapy, according to researchers.
Combining SBRT With ICIs Did Not Slow Progression in Solid Tumors Trial
Adding stereotactic body radiation therapy to immune checkpoint inhibitor therapy was safe but failed to improve progression-free and overall survival.
Certain Antibiotics May Reduce the Efficacy of Certain ICIs in Cancer Patients
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
Melanoma Diagnosis Linked to Increased Risk of Prostate Cancer
More than twofold increased risk of prostate cancer seen for men with first melanoma diagnosed 10 to 15 years before study recruitment
Disparities in Use of Immunotherapies Persist After FDA Approval
Some disparities that existed before FDA approval persisted after approval, and some new disparities emerged after FDA approval.
Therapeutic Advancements Have Facilitated Surgery Optimization, ASCO Officials Report
ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.
Longer Duration of Steroids May Affect Outcomes During Anti-PD-1 Treatment
The use of steroids for the treatment of immune-related adverse events may have survival consequences.
Melanoma Staging System Updated
Key changes include new N category descriptors, more stage III subgroups, new M1D designation.
Most Melanomas Arise From New Lesions, Not Moles
The findings showed that only 29.1% of the skin cancers started in moles patients already had.
- Loading...
Loading...
Loading... 
Loading...